Holen Sie sich die Stockscreener-App
12.33
6.20%
0.72
Schlusskurs vom Vortag:
$11.61
Offen:
$11.65
24-Stunden-Volumen:
425.67K
Relative Volume:
1.51
Marktkapitalisierung:
$382.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-7.8771
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
+3.53%
1M Leistung:
-6.16%
6M Leistung:
-32.44%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.47
$12.42
1-Wochen-Bereich:
$10.30
$12.51
52-Wochen-Spanne:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
12.33 | 382.88M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating - TipRanks
MBX Biosciences files IND application for MBX-4291 for obesity - BioWorld MedTech
MBX Biosciences announces IND application to FDA for MBX 4291 - TipRanks
MBX Biosciences Submits IND for Obesity Treatment - TipRanks
MBX Biosciences submits IND for once-monthly obesity treatment - Investing.com
MBX Biosciences Announces IND Submission Of MBX 4291, Its Long-Acting GLP1/GIP Receptor Co-Agonist Prodrug For The Treatment Of Obesity - MarketScreener
MBX Biosciences Announces IND Submission of MBX 4291, its - GlobeNewswire
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor ... - Eagle-Tribune
Bank of America Corp DE Makes New Investment in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Stifel reiterates buy rating on MBX Biosciences stock ahead of trial data - Investing.com Nigeria
Stifel reiterates buy rating on MBX Biosciences stock ahead of trial data By Investing.com - Investing.com South Africa
MBX Biosciences Announces Presentations on MBX 1416 at American Diabetes Association’s 85th Scientific Sessions - Nasdaq
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions - GlobeNewswire
MBX Biosciences Phase 1 Success: Revolutionary Weekly Treatment for Post-Bariatric Hypoglycemia Heads to Phase 2 - Stock Titan
MBX Biosciences Updates Corporate Presentation June 2025 - TipRanks
Nuveen Asset Management LLC Purchases Shares of 14,471 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
BNP Paribas Financial Markets Makes New Investment in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
mbx biosciences announces board changes and director elections - Investing.com Australia
mbx biosciences announces board changes and director elections By Investing.com - Investing.com South Africa
MBX Biosciences, Inc. Announces Departure of Carl L. Gordon from the Company's Board of Directors, Effective June 5, 2025 - marketscreener.com
MBX Biosciences Elects Directors at Annual Meeting - TipRanks
Deutsche Bank AG Buys New Position in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases Shares of 6,335 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy - Seeking Alpha
MBX Biosciences, Inc. (NYSE:MBX) Given Consensus Rating of “Buy” by Brokerages - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Shares Sold by Millennium Management LLC - Defense World
Northern Trust Corp Invests $1.67 Million in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences to Participate in June Investor Conferences - GlobeNewswire
MBX Biosciences Showcases Precision Peptide Pipeline at Two Major Healthcare Conferences This June - Stock Titan
Citadel Advisors LLC Grows Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
MBX Biosciences Reports Q1 2025 Financial Progress - TipRanks
MBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial Position - TipRanks
Stifel maintains MBX Biosciences stock Buy rating, $40 target By Investing.com - Investing.com Nigeria
Stifel maintains MBX Biosciences stock Buy rating, $40 target - Investing.com
MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Wells Fargo & Company MN Purchases Shares of 5,844 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Hypoglycemia Market Poised for Notable Growth by 2032, Fueled - openPR.com
MBX Biosciences Up 28%, Insider Buyers Are Up 19% - simplywall.st
MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Rating of “Buy” from Analysts - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Geode Capital Management LLC - Defense World
JMP maintains MBX Biosciences stock $38 target, upbeat on trial data - Investing.com Australia
Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth - Yahoo Finance
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences - The Manila Times
MBX Biosciences Reveals Growth Strategy at Citizens and RBC Healthcare Conferences: Key Updates Coming - Stock Titan
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mbx Biosciences Inc-Aktie (MBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| GORDON CARL L | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| ORBIMED ADVISORS LLC | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| ORBIMED ADVISORS LLC | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| Hawryluk P. Kent | President & CEO |
Feb 04 '25 |
Buy |
10.69 |
50,000 |
534,500 |
448,277 |
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):